Article info

Download PDFPDF
Adalimumab for the treatment of refractory active and inactive non-infectious uveitis

Authors

  • Jonathan TL Lee Centre for Eye Research Australia, University of Melbourne, East Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • William B Yates Department of Ophthalmology, Sydney Eye Hospital, Sydney, New South Wales, Australia Save Sight Institute, The University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Sophie Rogers Centre for Eye Research Australia, University of Melbourne, East Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Denis Wakefield School of Medical Sciences, University of New South Wales, Kensington, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Peter McCluskey Department of Ophthalmology, Sydney Eye Hospital, Sydney, New South Wales, Australia Save Sight Institute, The University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Lyndell L Lim Centre for Eye Research Australia, University of Melbourne, East Melbourne, Victoria, Australia Ocular Immunology Clinic, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Associate Professor Lyndell L Lim, Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC 3002, Australia; limllp{at}unimelb.edu.au
View Full Text

Citation

Lee JT, Yates WB, Rogers S, et al
Adalimumab for the treatment of refractory active and inactive non-infectious uveitis

Publication history

  • Received August 23, 2017
  • Revised January 25, 2018
  • Accepted January 31, 2018
  • First published February 19, 2018.
Online issue publication 
November 22, 2018

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.